Polg Related Mitochondrial Disorders is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
POLG-related mitochondrial disorders represent a spectrum of autosomal recessive diseases caused by mutations in the POLG gene (DNA polymerase gamma, catalytic subunit), located on chromosome 15q26.1[1]. POLG is the only DNA polymerase responsible for mitochondrial DNA (mtDNA) replication and maintenance in human cells[1]. These disorders are among the most common inherited mitochondrial diseases, characterized by mitochondrial DNA depletion and subsequent multi-system neurodegeneration. [1]
The POLG gene encodes the catalytic subunit of DNA polymerase gamma, essential for replicating the circular mitochondrial DNA genome[1]. Over 300 pathogenic variants in POLG have been identified, causing various clinical phenotypes[2]. [2]
Most patients have compound heterozygous mutations—inheritng different mutations from each carrier parent[1]. [3]
OMIM: 203700 [4]
Alpers syndrome, also known as mitochondrial DNA depletion syndrome 4A (MTDPS4A), is the most severe phenotype[1]. Clinical features include: [5]
Characterized by: [6]
A late-onset phenotype featuring:
Features:
POLG mutations impair the ability of DNA polymerase gamma to replicate mtDNA effectively[1]. This leads to:
The accumulation of mtDNA deletions and depletion over time leads to progressive cellular energy failure[1].
Supportive Care:
Metabolic Interventions:
A landmark 2025 Nature study described PZL-A, a first-in-class small-molecule activator that binds an allosteric site on POLG and restores function to mutant POLG enzymes[1]. This represents the first targeted therapy for POLG-related disorders and shows promise in cellular models from affected patients.
Prognosis varies significantly based on:
Alpers syndrome often has a rapidly progressive course, with survival into adolescence variable. Adult-onset forms may have a more indolent progression.
Mice with Polg mutations accumulate mtDNA deletions and display premature aging phenotypes, supporting the link between mtDNA maintenance defects and neurodegeneration[1]. These models are valuable for testing therapeutic interventions.
MERRF (Myoclonic Epilepsy with Ragged-Red Fibers) - associated with mtDNA mutations
MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes)
The study of Polg Related Mitochondrial Disorders has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
This section highlights recent publications relevant to this disease.